MedDataX Logo

Daily Protein Intake Distribution and MPS (ARCIII)

NCT ID: NCT02315014

Last Updated: 2014-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine whether a balanced total daily dietary protein distribution supplemented with whey protein during a weight-loss intervention will result in increased muscle protein synthesis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

whey protein

whey protein micelles

Group Type EXPERIMENTAL

whey protein

Intervention Type OTHER

whey protein.

placebo

calorie-free placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

placebo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

whey protein

whey protein.

Intervention Type OTHER

placebo

placebo.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Overweight/obese (BMI 27-40 kg/m2)
* Non-smokers
* Non-diabetic
* No history of hyperlipidemia
* Not taking medications thought to interfere with study
* Considered generally healthy

Exclusion Criteria

* Efforts to lose weight in previous 16 weeks
* Hyperlipidemia
* Blood pressure ≥ 140/90 mmHg
* Smoking
* Heart and other organ disease
* Type 2 diabetes
* Gastrointestinal disease
* Orthopedic injury interfering with exercise
* Use of certain medications (HRT, antihypertensives, diuretics, antiarythmia medications, antiresorptive agents, anabolic agents, hypoglycemic agents, and statins known to affect muscle i.e. Simvastatin and Zocor)
Minimum Eligible Age

60 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Société des Produits Nestlé (SPN)

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stuart Phillips, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

McMaster University

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12.12.NRC

Identifier Type: -

Identifier Source: org_study_id